Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

October 24, 2026

7

A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca. A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Related Articles

“A Nation Ceases To Be A Nation If It Can’t Protect Its Borders”: Fifth Circuit Backs Trump’s Mandatory Detention Policy

Netanyahu Locks Down West Bank, Launches Massive Operation After Two IDF Soldiers Killed

58% Of Americans Get Their News From Four Left-Leaning Aggregators; Study Finds

Latest Articles

“A Nation Ceases To Be A Nation If It Can’t Protect Its Borders”: Fifth Circuit Backs Trump’s Mandatory Detention Policy

Netanyahu Locks Down West Bank, Launches Massive Operation After Two IDF Soldiers Killed

58% Of Americans Get Their News From Four Left-Leaning Aggregators; Study Finds

AI funding fears rattle Wall Street. Here’s how we’re adjusting our portfolio

American embassies tighten security as Iran threat warnings intensify ahead of U.S. midterm elections